Tabassome Simon
Impact in
-
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism
Papers in
-
- Acute Myocardial Infarction Research 95
- Antiplatelet Therapy and Cardiovascular Diseases 40
- Heart Failure Treatment and Management 14
- Biochemistry 18
- Blood transfusion and management 18
- Co-authors
- Nicolas Danchin (120 shared papers)Jean Ferrières (69 shared papers)Philippe Gabríel Steg (47 shared papers)Murielle Mary‐Krause (6 shared papers)Élodie Drouet (19 shared papers)Étienne Puymirat (82 shared papers)Jessica L. Mega (3 shared papers)Céline Verstuyft (5 shared papers)
- Journals
- European Heart Journal (23 papers)Archives of cardiovascular diseases (20 papers)Circulation (15 papers)International Journal of Cardiology (12 papers)Journal of the American College of Cardiology (10 papers)
- Partner nations
- FranceUnited StatesUnited Kingdom
In The Last Decade
Tabassome Simon
367 papers receiving 20.1k citations
Tabassome Simon's Hit Papers
Peers
Comparison fields: 5 of 153
- Cardiology and Cardiovascular Medicine 7.1k
- Pharmacology 1k
- Internal Medicine 312
- Genetics 2.2k
- Nephrology 687
Countries citing papers authored by Tabassome Simon
This map shows the geographic impact of Tabassome Simon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tabassome Simon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tabassome Simon more than expected).
Fields of papers citing papers by Tabassome Simon
This network shows the impact of papers produced by Tabassome Simon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tabassome Simon. The network helps show where Tabassome Simon may publish in the future.
Co-authors
The 25 scholars most cited alongside Tabassome Simon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 391 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Genetic Determinants of Response to Clopidogrel and Cardiovascular Events Hit paper breakdown → | 2008 | 1384 |
| 2 | Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI Hit paper breakdown → | 2010 | 928 |
| 3 | Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study Hit paper breakdown → | 2009 | 894 |
| 4 | 2020 | 599 | |
| 5 | 2008 | 586 | |
| 6 | Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON–TIMI 38 trial: a pharmacogenetic analysis Hit paper breakdown → | 2010 | 498 |
| 7 | A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis Hit paper breakdown → | 2018 | 483 |
| 8 | B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction Hit paper breakdown → | 2013 | 475 |
| 9 | Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease Hit paper breakdown → | 2011 | 413 |
| 10 | Acute Myocardial Infarction Hit paper breakdown → | 2017 | 397 |
| 11 | 2016 | 351 | |
| 12 | Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up Hit paper breakdown → | 2016 | 338 |
| 13 | 2014 | 328 | |
| 14 | Fecal microbiota transplantation to maintain remission in Crohn’s disease: a pilot randomized controlled study Hit paper breakdown → | 2020 | 311 |
| 15 | 2013 | 292 | |
| 16 | Ticagrelor in Patients with Stable Coronary Disease and Diabetes Hit paper breakdown → | 2019 | 263 |
| 17 | Multivessel PCI Guided by FFR or Angiography for Myocardial Infarction Hit paper breakdown → | 2021 | 258 |
| 18 | Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial Hit paper breakdown → | 2019 | 244 |
| 19 | 2001 | 240 | |
| 20 | 2008 | 237 |
About Tabassome Simon
Tabassome Simon is a scholar working on Cardiology and Cardiovascular Medicine, Biochemistry, Infectious Diseases, Internal Medicine and Surgery, having authored 391 papers that have together received 20.9k indexed citations. Recurring topics across this work include Acute Myocardial Infarction Research (95 papers), Antiplatelet Therapy and Cardiovascular Diseases (40 papers), Lipoproteins and Cardiovascular Health (23 papers), Blood transfusion and management (18 papers), Heart Failure Treatment and Management (14 papers), COVID-19 Clinical Research Studies (14 papers), Venous Thromboembolism Diagnosis and Management (11 papers) and Inflammatory Bowel Disease (9 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (7.1k citations), Pharmacology (1k citations), Internal Medicine (312 citations), Genetics (2.2k citations) and Nephrology (687 citations). Tabassome Simon has collaborated with scholars based in France, United States and United Kingdom. Frequent co-authors include Nicolas Danchin, Jean Ferrières, Philippe Gabríel Steg, Murielle Mary‐Krause, Élodie Drouet, Étienne Puymirat, Jessica L. Mega, Céline Verstuyft, Laurent Becquemont and Nicolas F. Meneveau. Their work appears in journals such as European Heart Journal, Archives of cardiovascular diseases, Circulation, International Journal of Cardiology and Journal of the American College of Cardiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.